专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08895260B2 Screening assay for ribosomal antibiotics 有权
标题翻译：核糖体抗生素筛选试验
公开(公告)号：US08895260B2
公开(公告)日：2014-11-25
申请号：US12225706
申请日：2007-03-30
申请人： Erik Boettger , Andrea Vasella , Sven N. Hobbie
发明人： Erik Boettger , Andrea Vasella , Sven N. Hobbie
IPC分类号： C12Q1/18 , C12Q1/00 , C12N1/20
CPC分类号： C12N1/20 , C12Q1/18 , G01N2333/35
摘要： The present invention is directed to a method for identifying ribosomal antimicrobial substances being selective for microbial but not for mitochondrial and/or cytosolic ribosomes. Specifically, said method is directed to an assay that compares the interaction of a candidate ribosomal antimicrobial substance (i) in a bacterial strain with microbial ribosomes, and (ii) in a bacterial strain with chimeric mitochondrial bacterial ribosomes, and/or (iii) in a bacterial strain with chimeric cytosolic bacterial ribosomes. In a further aspect the present invention also relates to the use of bacterial strains with microbial ribosomes, and bacterial strains with chimeric mitochondrial bacterial ribosomes, and/or bacterial strains with chimeric cytosolic bacterial ribosomes for identifying ribosomal antimicrobial substance being selective for microbial but not for mitochondrial and/or cytosolic ribosomes. Furthermore, one or more of the above bacterial strains (i) to (iii) may be substituted by a functionally equivalent cell-free biological system.
摘要翻译：本发明涉及用于鉴定对微生物有选择性的核糖体抗微生物物质的方法，但不用于线粒体和/或胞质核糖体。具体地说，所述方法涉及比较细菌菌株中的候选核糖体抗微生物物质（i）与微生物核糖体的相互作用的测定法，和（ii）在具有嵌合线粒体细菌核糖体的细菌菌株中的相互作用，和/或（iii）在具有嵌合胞质细菌核糖体的细菌菌株中。在另一方面，本发明还涉及具有微生物核糖体的细菌菌株和具有嵌合线粒体细菌核糖体的细菌菌株和/或具有嵌合胞质细菌核糖体的细菌菌株用于鉴定对微生物有选择性的核糖体抗微生物物质，但不适用于线粒体和/或细胞溶质核糖体。此外，上述一种或多种上述细菌菌株（i）至（iii）可以被功能上等同的无细胞生物系统替代。

2. 发明申请

US20130165397A1 TREATMENT OF BACTERIAL INFECTIOUS DISEASES 有权
标题翻译：治疗细菌感染性疾病
公开(公告)号：US20130165397A1
公开(公告)日：2013-06-27
申请号：US13820258
申请日：2011-09-12
申请人： Erik Boettger , Andrea Vasella
发明人： Erik Boettger , Andrea Vasella
IPC分类号： A61K31/7036 , C07H15/224
CPC分类号： A61K31/70 , A61K31/7036 , C07H15/224 , C07H17/04 , Y02A50/402 , Y02A50/481
摘要： The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.
摘要翻译：本发明涉及人类细菌感染性疾病的新型药理学治疗。具体地说，本发明涉及式（I）的安普霉素或安普霉素衍生物用于治疗人类细菌感染性疾病的用途。据证实，阿帕霉素令人惊讶地没有预期的相关氨基糖苷类抗生素观察到的高水平的毒性，但实际上甚至比已用于人类药物（如庆大霉素）的化合物显着降低毒性。

3. 发明申请

US20090170150A1 Screening Assay for Ribosomal Antibiotics 有权
标题翻译：核糖体抗生素筛选试验
公开(公告)号：US20090170150A1
公开(公告)日：2009-07-02
申请号：US12225706
申请日：2007-03-30
申请人： Erik Boettger , Andrea Vasella , Sven N. Hobbie
发明人： Erik Boettger , Andrea Vasella , Sven N. Hobbie
IPC分类号： C12Q1/18
CPC分类号： C12N1/20 , C12Q1/18 , G01N2333/35
摘要： The present invention is directed to a method for identifying ribosomal antimicrobial substances being selective for microbial but not for mitochondrial and/or cytosolic ribosomes. Specifically, said method is directed to an assay that compares the interaction of a candidate ribosomal antimicrobial substance (i) in a bacterial strain with microbial ribosomes, and (ii) in a bacterial strain with chimeric mitochondrial bacterial ribosomes, and/or (iii) in a bacterial strain with chimeric cytosolic bacterial ribosomes. In a further aspect the present invention also relates to the use of bacterial strains with microbial ribosomes, and bacterial strains with chimeric mitochondrial bacterial ribosomes, and/or bacterial strains with chimeric cytosolic bacterial ribosomes for identifying ribosomal antimicrobial substance being selective for microbial but not for mitochondrial and/or cytosolic ribosomes. Furthermore, one or more of the above bacterial strains (i) to (iii) may be substituted by a functionally equivalent cell-free biological system.
摘要翻译：本发明涉及用于鉴定对微生物有选择性的核糖体抗微生物物质的方法，但不用于线粒体和/或胞质核糖体。具体地说，所述方法涉及比较细菌菌株中的候选核糖体抗微生物物质（i）与微生物核糖体的相互作用的测定法，和（ii）在细菌菌株中与嵌合的线粒体细菌核糖体的相互作用，和/或（iii）在具有嵌合胞质细菌核糖体的细菌菌株中。在另一方面，本发明还涉及具有微生物核糖体的细菌菌株和具有嵌合线粒体细菌核糖体的细菌菌株和/或具有嵌合胞质细菌核糖体的细菌菌株用于鉴定对微生物有选择性的核糖体抗微生物物质，但不适用于线粒体和/或细胞溶质核糖体。此外，上述一种或多种上述细菌菌株（i）至（iii）可以被功能上等同的无细胞生物系统替代。

4. 发明授权

US09271993B2 Treatment of bacterial infectious diseases 有权
标题翻译：治疗细菌性传染病
公开(公告)号：US09271993B2
公开(公告)日：2016-03-01
申请号：US13820258
申请日：2011-09-12
申请人： Erik Boettger , Andrea Vasella
发明人： Erik Boettger , Andrea Vasella
IPC分类号： A61K31/7036 , C07H15/224 , A61K31/70 , C07H17/04
CPC分类号： A61K31/70 , A61K31/7036 , C07H15/224 , C07H17/04 , Y02A50/402 , Y02A50/481
摘要： Novel pharmacological treatment of bacterial infectious diseases in humans by use of apramycin of formula (I) or apramycin derivatives having significantly low toxicity.
摘要翻译：通过使用式（I）的安普霉素或具有显着低毒性的阿普霉素衍生物，对人类细菌感染性疾病的新药理学治疗。

5. 发明授权

US08647641B2 Mycobacterium tuberculosis vaccine 有权
标题翻译：结核分枝杆菌疫苗
公开(公告)号：US08647641B2
公开(公告)日：2014-02-11
申请号：US13121215
申请日：2009-10-09
申请人： Erik Boettger , Peter Sander
发明人： Erik Boettger , Peter Sander
IPC分类号： A61K39/04
CPC分类号： A61K39/04 , A61K2039/522 , A61K2039/523
摘要： The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.
摘要翻译：本发明涉及结核分枝杆菌复合物的活分枝杆菌用于制备药物的用途，其中zmp1基因的功能失活，由这种分枝杆菌制备的药物组合物以及用于治疗和/或预防的方法使用所述药物组合物的疾病或医学病症。

6. 发明申请

US20110177120A1 MYCOBACTERIUM TUBERCULOSIS VACCINE 有权
公开(公告)号：US20110177120A1
公开(公告)日：2011-07-21
申请号：US13121215
申请日：2009-10-09
申请人： Erik Boettger , Peter Sander
发明人： Erik Boettger , Peter Sander
IPC分类号： A61K39/21 , A61K35/74 , A61K39/04 , A61K39/12 , A61K39/002 , A61K39/00 , A61K39/02 , A61K39/165 , A61K39/05 , A61K39/08 , A61P31/00 , A61P33/02 , A61P37/04 , A61P35/00 , C12N1/20 , C12N1/21
CPC分类号： A61K39/04 , A61K2039/522 , A61K2039/523
摘要： The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.
摘要翻译：本发明涉及结核分枝杆菌复合物的活分枝杆菌用于制备药物的用途，其中zmp1基因的功能失活，由这种分枝杆菌制备的药物组合物以及用于治疗和/或预防的方法使用所述药物组合物的疾病或医学病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式